Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,666 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
141
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Dietary Restriction, Exercise Training
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Not applicable Interventional Accepts healthy volunteers

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

NCT00609505
Conditions
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions
Telemedicine, Face-to-Face
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
4
States / cities
Henderson, North Carolina • Laurinburg, North Carolina • Lumberton, North Carolina + 1 more
Not listed No phase listed Observational

The Diabetic Foot Ulcer Registry

NCT02813161
Conditions
Diabetic Foot Ulcer Outcome, Quality of Patient Care
Interventions
cellular and tissue based therapy, negative pressure wound therapy, debridement, advanced wound therapy, Nutritional screening, off-loading, Hyperbaric oxygen Therapy
Biological · Device · Procedure + 1 more
Lead sponsor
U.S. Wound Registry
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
The Woodlands, Texas
Conditions
Androgen Insensitivity Syndrome, Metabolic Parameters in AIS, CAIS, PAIS and MAIS, Tumor Formation in AIS, CAIS, PAIS and MAIS, Sexual Function AIS, CAIS, PAIS and MAIS
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
8 Years to 99 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Kidney Disease, Sarcopenia
Interventions
Valine, EEA
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 4 Interventional Results available

Study of Oasis Ultra in Diabetic Foot Ulcers

NCT01835379
Conditions
Diabetic Foot Ulcer
Interventions
Oasis, Standard
Device · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Little Rock, Arkansas • Carlsbad, California • Fair Oaks, California + 12 more
Not yet recruiting Early Phase 1 Interventional

Phosphate & Kidney Stones

NCT07903961
Conditions
Kidney Stones, Calcium Oxalate Kidney Stones, Hypophosphatemia
Interventions
Neutral Phosphate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Gestational Diabetes Mellitus in Pregnancy, Pregnancy, High Risk
Interventions
Enhanced First Trimester GDM Screening, Routine Gestational Diabetes Screening
Diagnostic Test
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Congenital Adrenal Hyperplasia
Interventions
Tildacerfont/Placebo
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Conditions
Type 1 Diabetes, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
sodium bicarbonate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Diabetic Foot Ulcer
Interventions
Exercise
Behavioral
Lead sponsor
Mercer University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dietary Reversal of the Reprometabolic Syndrome

NCT07227766
Conditions
Obesity & Overweight, Infertility, Female
Interventions
Low-fat diet
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
dutogliptin, placebo, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Tempe, Arizona • Long Beach, California • Lynwood, California + 18 more
Conditions
Wound Healing, Diabetes
Interventions
Pulsatile Intravenous Insulin Therapy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Conditions
Congenital Adrenal Hyperplasia
Interventions
Pre-Screening
Other
Lead sponsor
Adrenas Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diabetes, Diabetic Retinopathy
Interventions
No intervention
Device
Lead sponsor
iHealthScreen Inc
Industry
Eligibility
22 Years and older
Enrollment
935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond Hill, New York
Conditions
Gestational Diabetes, Pregnancy, Obesity
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions
tolvaptan, placebo matching tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more
Conditions
Diabetic Kidney Disease
Interventions
Finerenone 10 MG, Empagliflozin 10 MG
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Hyperuricemia, Albuminuria, Type 2 Diabetes
Interventions
Verinurad 9 mg+Febuxostat 80 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Canyon Country, California • Chula Vista, California • Corona, California + 12 more
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
Interventions
calcium, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Madison, Wisconsin
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey